Last reviewed · How we verify
rhDNAse
rhDNAse is a recombinant human deoxyribonuclease that breaks down extracellular DNA in airway secretions to reduce mucus viscosity.
rhDNAse is a recombinant human deoxyribonuclease that breaks down extracellular DNA in airway secretions to reduce mucus viscosity. Used for Cystic fibrosis to improve pulmonary function and reduce respiratory exacerbations.
At a glance
| Generic name | rhDNAse |
|---|---|
| Also known as | Brand Name: Pulmozyme |
| Sponsor | The Hospital for Sick Children |
| Drug class | Recombinant enzyme |
| Target | Extracellular DNA (deoxyribonucleic acid) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonary |
| Phase | FDA-approved |
Mechanism of action
In cystic fibrosis and other conditions with thick airway secretions, neutrophil death releases large amounts of DNA that increases sputum viscosity and impairs clearance. rhDNAse cleaves this extracellular DNA, reducing mucus thickness and improving airway function. This allows better mucociliary clearance and reduces airway obstruction.
Approved indications
- Cystic fibrosis to improve pulmonary function and reduce respiratory exacerbations
Common side effects
- Voice hoarseness
- Pharyngitis
- Laryngitis
- Rash
- Chest pain
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection
- Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic (NA)
- Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (PHASE2)
- Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. (PHASE1)
- VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema (NA)
- Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer. (PHASE2)
- Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhDNAse CI brief — competitive landscape report
- rhDNAse updates RSS · CI watch RSS
- The Hospital for Sick Children portfolio CI